CN102395883B - 用于监控患者的生物标志物 - Google Patents

用于监控患者的生物标志物 Download PDF

Info

Publication number
CN102395883B
CN102395883B CN201080016800.2A CN201080016800A CN102395883B CN 102395883 B CN102395883 B CN 102395883B CN 201080016800 A CN201080016800 A CN 201080016800A CN 102395883 B CN102395883 B CN 102395883B
Authority
CN
China
Prior art keywords
patient
level
immunogenic composition
activated
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080016800.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102395883A (zh
Inventor
B·阿克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of CN102395883A publication Critical patent/CN102395883A/zh
Application granted granted Critical
Publication of CN102395883B publication Critical patent/CN102395883B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080016800.2A 2009-04-17 2010-04-12 用于监控患者的生物标志物 Expired - Fee Related CN102395883B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305328.8 2009-04-17
EP09305328 2009-04-17
PCT/EP2010/054743 WO2010119003A1 (en) 2009-04-17 2010-04-12 Biomarker for monitoring patients

Publications (2)

Publication Number Publication Date
CN102395883A CN102395883A (zh) 2012-03-28
CN102395883B true CN102395883B (zh) 2015-12-02

Family

ID=42270292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080016800.2A Expired - Fee Related CN102395883B (zh) 2009-04-17 2010-04-12 用于监控患者的生物标志物

Country Status (26)

Country Link
US (2) US20120058493A1 (https=)
EP (1) EP2419728B1 (https=)
JP (1) JP5661738B2 (https=)
KR (1) KR20120027146A (https=)
CN (1) CN102395883B (https=)
AU (1) AU2010237215B2 (https=)
BR (1) BRPI1010512A2 (https=)
CA (1) CA2759050A1 (https=)
CO (1) CO6440591A2 (https=)
CR (1) CR20110513A (https=)
CY (1) CY1114910T1 (https=)
DK (1) DK2419728T3 (https=)
ES (1) ES2445146T3 (https=)
HR (1) HRP20140262T1 (https=)
IL (1) IL214917A (https=)
MX (1) MX2011010920A (https=)
NZ (1) NZ594896A (https=)
PL (1) PL2419728T3 (https=)
PT (1) PT2419728E (https=)
RU (1) RU2555340C2 (https=)
SG (1) SG175060A1 (https=)
SI (1) SI2419728T1 (https=)
SM (1) SMT201400046B (https=)
TW (1) TWI426270B (https=)
WO (1) WO2010119003A1 (https=)
ZA (1) ZA201107545B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168550A1 (ja) * 2012-05-11 2013-11-14 味の素株式会社 癌免疫療法の評価方法、癌免疫療法評価装置、癌免疫療法評価プログラム、癌免疫療法評価システムおよび情報通信端末装置
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
US20200353107A1 (en) * 2017-12-08 2020-11-12 Stc.Unm In vivo imaging of tumor infiltration leukocytes
CN114859057A (zh) * 2022-04-13 2022-08-05 江苏省中医院 人结直肠癌或人结直肠癌转移的预测性生物标志物及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE19520606B4 (de) 1995-06-06 2004-04-08 Roche Diagnostics Gmbh Vorrichtung zur optischen Untersuchung von Oberflächen
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2773885B1 (fr) 1998-01-16 2000-03-03 Elf Antar France Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode
JP3119228B2 (ja) 1998-01-20 2000-12-18 日本電気株式会社 液晶表示パネル及びその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
CA2362367C (en) 1999-02-04 2004-08-03 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
AU2003261252A1 (en) 2002-07-26 2004-02-16 Myomend, Inc. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
PL1896051T3 (pl) * 2005-06-28 2015-04-30 Oncothyreon Inc Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1)
CA2668942A1 (en) * 2006-12-05 2008-06-12 Transgene S.A. Means and method for raising improved immune response
BRPI0913108A2 (pt) * 2008-05-29 2017-06-20 Trangene S A método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso de níveis de células exterminadores naturais ativadas como um biomarcador, e, kit

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Effective Treatment of Preexisting Melanoma with Whole Cell Vaccines Expressing α(1,3)-Galactosyl Epitopes;Gabriela R. Rossi,et al;《Cancer Res.》;20051115;第65卷(第22期);摘要，第10556页右栏第18行至第10559页左栏第10行，图2、4 *
Reduced expression of CD69 and adhesion molecules of T lymphocytes in asthmatic children receiving immunotherapy;Jing-Long Huang,et al;《Pediatric Allergy and Immunology》;20021231;第13卷(第6期);摘要，第427页右栏第35行至第430页左栏第8行，图1a、2a *
The peripheral blood leukocyte phenotype in patients with breast cancer: Effect of doxorubicin/paclitaxel combination chemotherapy;Melichar Bohuslav, et al;《IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY》;20011231;第23卷(第2期);摘要，表1，表2，第165页第9-38行，第167页第3-4行，第170页第15-31行 *
Triggering of T cell-mediated immune responses by allogenic tumor cell vaccine in patients with oral cancer;DEVARAPU SATISH K ET AL;《IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY》;20061231;第28卷(第3期);摘要 *

Also Published As

Publication number Publication date
JP2012524248A (ja) 2012-10-11
MX2011010920A (es) 2011-11-04
PL2419728T3 (pl) 2014-05-30
SG175060A1 (en) 2011-11-28
HK1163246A1 (en) 2012-09-07
CN102395883A (zh) 2012-03-28
SMT201400046B (it) 2014-05-07
EP2419728A1 (en) 2012-02-22
AU2010237215B2 (en) 2014-05-01
US20120058493A1 (en) 2012-03-08
RU2555340C2 (ru) 2015-07-10
WO2010119003A1 (en) 2010-10-21
KR20120027146A (ko) 2012-03-21
HRP20140262T1 (hr) 2014-04-25
TW201040530A (en) 2010-11-16
AU2010237215A1 (en) 2011-09-22
NZ594896A (en) 2013-07-26
CO6440591A2 (es) 2012-05-15
IL214917A0 (en) 2011-11-30
IL214917A (en) 2016-03-31
CY1114910T1 (el) 2016-12-14
EP2419728B1 (en) 2014-01-08
US20140141039A1 (en) 2014-05-22
DK2419728T3 (da) 2014-02-03
RU2011146419A (ru) 2013-05-27
TWI426270B (zh) 2014-02-11
SI2419728T1 (sl) 2014-03-31
CA2759050A1 (en) 2010-10-21
JP5661738B2 (ja) 2015-01-28
CR20110513A (es) 2012-01-06
PT2419728E (pt) 2014-03-12
BRPI1010512A2 (pt) 2016-03-15
ES2445146T3 (es) 2014-02-28
ZA201107545B (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CN102483405B (zh) 用于选择患者的生物标志物及相关方法
CN102395883B (zh) 用于监控患者的生物标志物
CN102362184B (zh) 用于监控患者的生物标志物
JP5642666B2 (ja) 患者選択のためのバイオマーカーおよび関連方法
HK1163246B (en) Biomarker for monitoring patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151202

Termination date: 20170412